

## 51-102F3 Material Change Report [F]

### Item 1 Name and Address of Company

Nirvana Life Sciences  
2110, 650 West Georgia Street  
Vancouver, BC V6B 4N8

### Item 2 Date of Material Change

August 4, 2022

### Item 3 News Release

The news release dated August 4, 2022 was disseminated through Canada Stockwatch and Market News under section 7.1 of National Instrument 51-102.

### Item 4 Summary of Material Change

Please refer to attached news release.

### Item 5 Full Description of Material Change

#### 5.1 Full Description of Material Change

Please refer to attached news release.

#### 5.2 Disclosure for Restructuring Transactions

N/A

### Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

N/A

### Item 7 Omitted Information

N/A

### Item 8 Executive Officer

Bruce Clark, Chief Executive Officer

### Item 9 Date of Report

August 16, 2022

## NIRVANA APPOINTS NEW CHIEF FINANCIAL OFFICER

VANCOUVER, B.C. August 4, 2022 (NEWSFILE) - Nirvana Life Sciences Inc., (CSE:NIRV) (“Nirvana” or the “Company”) a Canadian based life sciences company aimed at developing non-addictive chronic pain and addiction treatment products announces that Connie Hang has resigned as Chief Financial Officer of the Company. The Company thanks Ms. Hang for her work as CFO over the last 2 years, she will continue serving the Company as a Contractor.

Annie Storey, CPA, CA, BBA has been appointed as Chief Financial Officer, effective immediately. Ms. Storey, a director of the Company since 2017, brings over 25 years’ experience in accounting, auditing, financial reporting and corporate services for Canadian and US public companies in the mining, entertainment and biotechnology sectors.

Ms Storey has a keen interest in the development new approaches to manage addictions and currently serves as a director of the advocacy group Moms Stop the Harm.

### **About Nirvana Life Sciences**

Nirvana Life Sciences Inc. (CSE:NIRV) is an innovator in the emerging Psychedelic space. Its business model combines the development of novel formulations for drug development with the development of laboratory space to support ongoing development and manufacturing. At Nirvana, we believe that psilocibin derived medicines can play a leading role in reducing the impacts of the opioids crisis and build healthier communities. For more information visit <https://nirvanalifescience.com/>

For further information:

Bruce Clark

[CEOinfo@nirvanalifescience.com](mailto:CEOinfo@nirvanalifescience.com)

Phone: 604-401-8100

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

### **Forward-Looking Statements**

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove

to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement